SEC Comment Letter for enVVeno Medical Corp (NVNO, NVNBW) (CIK 0001661053) (NVNO) — May 21, 2019
enVVeno Medical Corp (NVNO, NVNBW) (CIK 0001661053)
Date: May 21, 2019 · CIK: 0001661053 · Accession: 0000000000-19-008730
AI Filing Summary & Sentiment
File numbers found in text: 333-230598
Letter
April 4, 2019 Robert A. Berman Chief Executive Officer Hancock Jaffe Laboratories, Inc. 70 Doppler Irvine, CA 92618 Re:Hancock Jaffe Laboratories, Inc. Registration Statement on Form S-1 Filed March 29, 2019 File No. 333-230598 Dear Mr. Berman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Michael Fay at 202-551-3812 with any questions. Sincerely, Division of Corporation Finance Office of Electronics and Machinery cc: David Selengut, Esq.
Show Raw Text
April 4, 2019
Robert A. Berman
Chief Executive Officer
Hancock Jaffe Laboratories, Inc.
70 Doppler
Irvine, CA 92618
Re:Hancock Jaffe Laboratories, Inc.
Registration Statement on Form S-1
Filed March 29, 2019
File No. 333-230598
Dear Mr. Berman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Michael Fay at 202-551-3812 with any questions.
Sincerely,
Division of Corporation Finance
Office of Electronics and Machinery
cc: David Selengut, Esq.